Molecular Partners reports key financials for H1 18 and corporate highlights for the second quarter 2018: Promising MP0250 clinical data in oncology and positive abicipar phase 3 efficacy data presented

By | Uncategorized | No Comments

Molecular Partners announces its unaudited financial results for the first half-year 2018, including promising updated data on the phase 2 trial of its lead oncology asset MP0250 and the positive phase 3 topline data for abicipar, as announced on July 19, 2018 by the company’s strategic partner Allergan.

Read More